GLP-1 and Peptide Supply Chain in 2026: What Telehealth and Med Spa Clinics Actually Need to Track

The FDA declared the semaglutide shortage resolved back in February 2025, with tirzepatide's shortage having ended a few months before that. On paper, that should mean supply problems are behind the industry. In practice, clinics are still dealing with delays, allocation limits, and dose-specific shortages — because "the shortage is over" and "supply is easy" turned out to be two very different statements. Here's what's actually driving that gap, and how a telehealth or med spa clinic should be managing it heading into the back half of 2026.

Why "Shortage Resolved" Didn't Mean "Problem Solved"

GLP-1 prescription volume grew from roughly 680,000 monthly prescriptions in early 2020 to well over 4 million by mid-2025 — an increase the underlying distribution infrastructure is still catching up to. Manufacturer production, wholesaler allocation policies, pharmacy fulfillment timelines, and shifting compounding regulations all interact in ways that can make a product technically "available" while still being hard to actually get in the specific dose or package size a given clinic needs.

Demand isn't predictable in the way clinics used to plan around, either. Social media trends, referral surges, seasonal weight-loss interest, and a growing base of long-term maintenance patients all move the needle. Forecasting based on last month's order isn't sufficient anymore — clinics need to be tracking active patient counts, new starts, dose escalations, and follow-up schedules together to anticipate what they'll actually need.

The Compliance Layer Has Tightened Considerably

Supply access and compliance are now tightly linked, and this is where a lot of clinics are still operating on outdated assumptions.

Compounding of GLP-1 medications is far more restricted than it was during the shortage years. A 503A pharmacy can only compound a GLP-1 for a documented clinical need — a genuine allergy to an inactive ingredient in the commercial product, for example — not for cost or convenience. And as of an April 2026 FDA proposal, semaglutide, tirzepatide, and liraglutide may be formally excluded from the 503B bulk drug substances list entirely, which would effectively end large-scale outsourcing-facility compounding of these medications. That proposal's public comment period, originally set to close in late June, was extended and now runs through July 30, 2026 — meaning a final determination is still pending as this is written, and clinics should expect the outcome to land sometime after that date.

Clinics still using compounded semaglutide or tirzepatide without genuine, documented, patient-specific clinical need are operating with real exposure right now, regardless of how things worked in 2023 or 2024.

Documentation Becomes More Important, Not Less, When Supply Is Tight

When supply gets constrained and protocols have to flex, thin documentation is the thing that turns a routine substitution into a compliance problem. Every initial GLP-1 visit should have a complete record: BMI and weight history, relevant comorbidities, a full medication review, contraindication screening, informed consent, and a documented treatment plan including drug and titration schedule. State boards specifically look for contraindication screening and informed consent happening at the same visit as the prescription — not retrofitted afterward. Any dose change, missed dose, medication switch, or adverse event needs to be documented clearly and reported where required.

What Supply Volatility Does to the Patient Experience

Supply disruption isn't just an inventory problem — it directly affects whether patients stay in treatment. More than half of GLP-1 patients discontinue within a year, frequently over cost or access friction, and supply hiccups at the wrong moment make that worse. The clinics that hold onto patients through disruption are the ones that get ahead of the conversation: setting expectations up front about possible delays, how refills work, dose-specific availability, and what happens if a specific product isn't available that month. Overpromising and then falling short erodes trust fast; a clear, honest heads-up rarely does.

A basic refill and follow-up system — reminders, scheduled check-ins, and clear staff ownership over supply monitoring versus clinical questions — prevents a lot of this from becoming a crisis in the first place. If nobody owns a given step, it gets missed, and the patient is the one who feels it.

Inventory Planning That Actually Matches Reality

Good GLP-1 inventory planning accounts for new starts, titration, maintenance patients, supplier lead times, and expiration — not just a flat monthly order based on headcount. Segmenting your patient list by treatment stage (new, titrating, maintenance, paused, discontinued) keeps ordering aligned with real, current demand instead of a stale average. A simple reorder threshold — based on average weekly use, supplier lead time, and a reasonable buffer — beats waiting until you're out and placing a rushed, more expensive emergency order.

Cold-chain handling matters throughout: use a first-expire-first-out approach, train staff on proper receiving and storage, and document the process. Waste from missed expiration dates is a direct hit to margin on medications that are expensive to begin with.

Vetting Vendors Beyond Price

Choosing a pharmacy or supplier partner should go well beyond who's cheapest. Ask directly about typical shipping times, how backorders get communicated, allocation policy during demand spikes, and how quickly you'll be told about supply changes — a vendor who goes quiet when supply tightens is a real liability. On the compliance side, confirm pharmacy licensing, 503A or 503B status, standing with state boards, and get current certificates of analysis rather than relying on a vendor's word. The lowest-priced option is rarely the one offering the safest, most fully documented process.

Protecting Margins Without Cutting Corners

Supply strain hits margins from multiple directions at once — higher per-unit costs, rush-order fees, spoiled product, and staff time lost chasing inventory problems instead of treating patients. Knowing your real, fully loaded cost per GLP-1 patient — product, supplies, staff time, consult time, documentation, and waste — is the only way to price sustainably and catch where money is actually leaking. Reactive, scattered ordering across too many vendors tends to drive costs up quietly; a centralized, planned ordering process protects margin in a way that's easy to overlook until it's already a problem.

What Clinics Should Do This Month

A quick operational check that pays off: list active patients by treatment stage, confirm your reorder threshold still matches current usage, audit whether your suppliers are actually reliable on fulfillment and communication, review intake and consent language for gaps, update patient communication templates for transparency around supply, and make sure everyone on staff knows who owns which piece of the supply chain. If clinical and operations teams are making decisions independently of each other, patients notice the seams.

How Wellness MD Group Supports This

Supply chain resilience isn't separate from compliance — it's part of the same infrastructure. Wellness MD Group builds vendor and pharmacy account access, physician-approved protocols, and EHR guidance into every client engagement, so sourcing decisions are backed by the same medical director oversight that governs the rest of a clinic's clinical program, rather than treated as a purely operational side task.

The Bottom Line

"Shortage resolved" was never the same claim as "supply is simple." Clinics that treat GLP-1 and peptide sourcing as an ongoing, actively managed function — tied to real documentation, vetted vendors, and physician oversight — are the ones positioned to keep patients on therapy through the next disruption, whatever form it takes.